Massimo Broggini
About
In The Last Decade
Massimo Broggini
232 papers receiving 7.4k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Molecular Biology 4.8k
- Oncology 3.1k
- Cancer Research 1.4k
- Pulmonary and Respiratory Medicine 1.1k
- Pathology and Forensic Medicine 633
Countries citing papers authored by Massimo Broggini
This map shows the geographic impact of Massimo Broggini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Broggini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Broggini more than expected).
Fields of papers citing papers by Massimo Broggini
This network shows the impact of papers produced by Massimo Broggini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Broggini. The network helps show where Massimo Broggini may publish in the future.
Co-authorship network of co-authors of Massimo Broggini
This figure shows the co-authorship network connecting the top 25 collaborators of Massimo Broggini. A scholar is included among the top collaborators of Massimo Broggini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Massimo Broggini. Massimo Broggini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 4 | |
| 3 | 14 | |
| 4 | 4 | |
| 5 | 20 | |
| 6 | 21 | |
| 7 | KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. | 10 |
| 8 | 64 | |
| 9 | 51 | |
| 10 | 2 | |
| 11 | 112 | |
| 12 | 30 | |
| 13 | Nemorubicin: A doxorubicin-like structure with a novel mechanism of action different from anthracyclines | 2 |
| 14 | 103 | |
| 15 | Gene expression analysis of Manumycin, a natural farnesyltransferase (FTase) inhibitor, in drug-resistant IL-6-producing myeloma cells. | 3 |
| 16 | Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. | 48 |
| 17 | Response to UV and cisplatin-induced damage in human ovarian cancer cells overexpressing XPB and expressing or not a wild type p53 | 1 |
| 18 | 7 | |
| 19 | Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice. | 39 |
| 20 | Differential distribution of antitumor agents in primary and secondary tumors. | 35 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.